Famous drug company Elli Lily on Thursday launched weekly injection Maunzaro (Tirjeetide) for obesity and type 2 diabetes in India. The company has received approval from India’s Central Drug Standards Control Organization (CDSCO) to launch this drug in India. According to the news of Moneycontrol, however, the company has not yet discussed the price of Maunzaro in India. There is a strong demand for silence in America and Europe. Its launch in India is part of Lily’s comprehensive strategy to expand access to innovative remedies in emerging markets.
Preparations are being made to ensure cheap access to medicine
According to the news, the company is working with healthcare providers, insurers and policy makers to ensure cheap access to medicine. Maunzaro activates both GIP and GLP-1 hormone receptors, showing significant weight loss and blood sugar control in diagnostic tests. GLP-1, or glucagon-like peptide-1, are hormones produced in the human body that are important in controlling blood sugar levels and appetite.
Major public health challenge is obesity and diabetes
Lily India President and General Manager Vinslo Tucker said that the double burden of obesity and type 2 diabetes is emerging as a major public health challenge in India. The company is committed to cooperating with the government and the industry for improvement in prevention and management. According to the news, in an American study of Tirzepetides in obese people, known as the Surmount-1 clinical trial, Maunzaro gained 21.8 kg on the highest dose (15mg) in 72 weeks and the lowest dose on the highest dose (15mg) and the lowest dose on the lowest dose and 15.4 kg.
Additionally, one in three patients lost more than 25% of his body weight, which is a significant higher than 1.5% percentage than seen in the Plessibo group. Dr. Manish Mistry, Senior Medical Director, Lily India, said that in India, there will be a new view of the metabolic health management. “
Latest business news
